HomeAboutRankingsData Sources
© 2026 GeneE
🧬
GeneE
10 sources retrieved · Most recent: April 2026 · Index updated 15 days ago
ⓘGeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
OSGIN1
oxidative stress induced growth inhibitor 1
Chromosome 16 · 16q23.3
NCBI Gene: 29948Ensembl: ENSG00000140961.15HGNC: HGNC:30093UniProt: Q9UJX0
35PubMed Papers
20Diseases
0Drugs
0Pathogenic Variants
DATA QUALITY
✓ Experimental GO Evidence✓ Swiss-Prot Reviewed
protein bindinggrowth factor activitynegative regulation of cell growthsignal transductionAbnormality of the livermusculoskeletal system diseasetype 2 diabetes mellitusaging
✦AI Summary

OSGIN1 is a monooxygenase with dual functions in cellular stress response and cytokinesis regulation. Mechanistically, OSGIN1 catalyzes monooxygenase activity to stabilize intercellular bridges during late cytokinesis and promotes RHOA activity at the midbody, facilitating abscission 1. OSGIN1 regulates differentiation and proliferation through modulation of cell death pathways 23. In disease contexts, OSGIN1 exhibits context-dependent roles. In ferroptosis resistance, OSGIN1 directly enhances GCLM activity to promote glutathione production, mitigating oxidative stress in pancreatic ductal adenocarcinoma 4. OSGIN1 acts downstream of NRF2 signaling in response to oxidative stress, with upregulation observed in cigarette smoke-induced endothelial detachment 5 and cystine-mediated triple-negative breast cancer survival 6. Conversely, OSGIN1 functions as a tumor suppressor in breast cancer, where docosahexaenoic acid induces OSGIN1 expression through PI3K/Akt/Nrf2 signaling to promote apoptosis 7. OSGIN1 also serves as a FXR target gene protecting against cisplatin-induced acute kidney injury 8 and pancreatitis via autophagy restoration 9. Clinically, OSGIN1 expression correlates with prognosis in multiple cancers and appears dysregulated in hepatocellular carcinoma 10, positioning it as both a therapeutic target and potential biomarker.

Sources cited
1
Mechanistically, OSGIN1 catalyzes monooxygenase activity to stabilize intercellular bridges during late cytokinesis and promotes RHOA activity at the midbody, facilitating abscission .
PMID: 38442170
2
In ferroptosis resistance, OSGIN1 directly enhances GCLM activity to promote glutathione production, mitigating oxidative stress in pancreatic ductal adenocarcinoma .
PMID: 39571229
3
OSGIN1 acts downstream of NRF2 signaling in response to oxidative stress, with upregulation observed in cigarette smoke-induced endothelial detachment and cystine-mediated triple-negative breast cancer survival .
PMID: 36804807
4
OSGIN1 acts downstream of NRF2 signaling in response to oxidative stress, with upregulation observed in cigarette smoke-induced endothelial detachment and cystine-mediated triple-negative breast cancer survival .
PMID: 38600165
5
Conversely, OSGIN1 functions as a tumor suppressor in breast cancer, where docosahexaenoic acid induces OSGIN1 expression through PI3K/Akt/Nrf2 signaling to promote apoptosis .
PMID: 28807874
6
OSGIN1 also serves as a FXR target gene protecting against cisplatin-induced acute kidney injury and pancreatitis via autophagy restoration .
PMID: 35767918
7
OSGIN1 also serves as a FXR target gene protecting against cisplatin-induced acute kidney injury and pancreatitis via autophagy restoration .
PMID: 36405253
8
Clinically, OSGIN1 expression correlates with prognosis in multiple cancers and appears dysregulated in hepatocellular carcinoma , positioning it as both a therapeutic target and potential biomarker.
PMID: 40668533
Disease Associationsⓘ20
Abnormality of the liverOpen Targets
0.40Weak
musculoskeletal system diseaseOpen Targets
0.32Weak
type 2 diabetes mellitusOpen Targets
0.32Weak
agingOpen Targets
0.31Weak
ovarian cancerOpen Targets
0.08Suggestive
pancreatitisOpen Targets
0.06Suggestive
neoplasmOpen Targets
0.04Suggestive
non-small cell lung carcinomaOpen Targets
0.04Suggestive
myopathyOpen Targets
0.03Suggestive
atherosclerosisOpen Targets
0.02Suggestive
hepatocellular carcinomaOpen Targets
0.02Suggestive
mastodyniaOpen Targets
0.02Suggestive
diabetic ketoacidosisOpen Targets
0.02Suggestive
cancerOpen Targets
0.02Suggestive
chronic obstructive pulmonary diseaseOpen Targets
0.02Suggestive
triple-negative breast cancerOpen Targets
0.02Suggestive
breast cancerOpen Targets
0.02Suggestive
SepsisOpen Targets
0.01Suggestive
Alzheimer diseaseOpen Targets
0.01Suggestive
cirrhosis of liverOpen Targets
0.01Suggestive
Pathogenic Variants
No pathogenic variants reported on ClinVar for this gene.
View on ClinVar ↗
Related Genes
OSGIN2Shared pathway100%SERTAD2Shared pathway100%SERTAD3Shared pathway100%NAIF1Shared pathway100%ST7LShared pathway100%WFDC1Shared pathway50%
Tissue Expression6 tissues
Liver
100%
Lung
9%
Ovary
4%
Heart
2%
Brain
2%
Bone Marrow
1%
Gene Interaction Network
Click a node to explore
OSGIN1OSGIN2SERTAD2SERTAD3NAIF1ST7LWFDC1
PROTEIN STRUCTURE
Preparing viewer…
AlphaFoldAI-predicted · UniProt Q9UJX0
View on AlphaFold ↗
Constraintⓘ
LOEUFⓘ
1.43LoF Tolerant
pLIⓘ
0.00Tolerant
Observed/Expected LoF1.00 [0.71–1.43]
RankingsWhere OSGIN1 stands among ~20K protein-coding genes
  • #11,027of 20,598
    Most Researched35
  • #14,740of 17,882
    Most Constrained (LOEUF)1.43
Genes detectedOSGIN1
Sources retrieved10 papers
Response time—
📄 Sources
10▼
1
Farnesoid X receptor protects against cisplatin-induced acute kidney injury by regulating the transcription of ferroptosis-related genes.
PMID: 35767918
Redox Biol · 2022
1.00
2
A Nrf2-OSGIN1&2-HSP70 axis mediates cigarette smoke-induced endothelial detachment: implications for plaque erosion.
PMID: 36804807
Cardiovasc Res · 2023
0.90
3
Therapeutic implication of oxidative stress-induced growth inhibitor 1 (OSGIN1) in cancer.
PMID: 40097807
Oncogene · 2025
0.80
4
Activation of Pancreatic Acinar FXR Protects against Pancreatitis via Osgin1-Mediated Restoration of Efficient Autophagy.
PMID: 36405253
Research (Wash D C) · 2022
0.70
5
NRF2 activation by cysteine as a survival mechanism for triple-negative breast cancer cells.
PMID: 38600165
Oncogene · 2024
0.60